PT86651A - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number: PT86651A
Authority: PT; Portugal
Prior art keywords: chemical compounds; compounds; chemical
Prior art date: 1987-02-02

Application number

PT86651A

Other languages

English (en)

Other versions

PT86651B (pt

Inventor

William John Coates

Original Assignee

Smith Kline French Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-02

Filing date

1988-01-28

Publication date

1988-02-01

1987-02-02 Priority claimed from GB878702301A external-priority patent/GB8702301D0/en

1987-02-02 Priority claimed from GB878702300A external-priority patent/GB8702300D0/en

1988-01-28 Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab

1988-02-01 Publication of PT86651A publication Critical patent/PT86651A/pt

1992-02-28 Publication of PT86651B publication Critical patent/PT86651B/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT86651A 1987-02-02 1988-01-28 Processo de preparacao de derivados da purinona PT86651B (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878702301A GB8702301D0 (en)	1987-02-02	1987-02-02	Chemical compounds
GB878702300A GB8702300D0 (en)	1987-02-02	1987-02-02	Chemical compounds

Publications (2)

Publication Number	Publication Date
PT86651A true PT86651A (pt)	1988-02-01
PT86651B PT86651B (pt)	1992-02-28

Family

ID=26291861

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT86651A PT86651B (pt)	1987-02-02	1988-01-28	Processo de preparacao de derivados da purinona

Country Status (10)

Country	Link
US (1)	US4885301A (pt)
EP (1)	EP0293063B1 (pt)
AU (1)	AU599452B2 (pt)
CA (1)	CA1303037C (pt)
DE (1)	DE3869205D1 (pt)
DK (1)	DK40788A (pt)
ES (1)	ES2033423T3 (pt)
GR (1)	GR3003956T3 (pt)
IE (1)	IE880213L (pt)
PT (1)	PT86651B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8809481D0 (en) *	1988-04-21	1988-05-25	Smith Kline French Lab	Chemical compounds
GB8814352D0 (en) *	1988-06-16	1988-07-20	Smith Kline French Lab	Chemical compounds
US5075310A (en) *	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) *	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
US5250534A (en) *	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9213623D0 (en) *	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
US5734053A (en) *	1992-06-26	1998-03-31	Pfizer Inc	Purinone antianginal agents
FI951367A (fi) *	1994-03-28	1995-09-29	Japan Energy Corp	Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5696159A (en) *	1994-08-03	1997-12-09	Cell Pathways, Inc.	Lactone compounds for treating patients with precancerous lesions
US5776962A (en) *	1994-08-03	1998-07-07	Cell Pathways, Inc.	Lactone compounds for treating patient with precancerous lesions
GB9423910D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
DE19501480A1 (de) *	1995-01-19	1996-07-25	Bayer Ag	9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US6060477A (en) *	1995-06-07	2000-05-09	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en)	1995-06-07	2001-07-17	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en)	1995-06-07	2001-05-15	Cell Pathways, Inc.	Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US5874440A (en) *	1995-06-07	1999-02-23	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en)	1995-06-07	2001-03-13	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5858694A (en) *	1997-05-30	1999-01-12	Cell Pathways, Inc.	Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) *	1997-05-30	2002-08-20	Cell Pathways, Inc.	Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
EP2295436A1 (de) *	1997-11-12	2011-03-16	Bayer Schering Pharma AG	2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
US5852035A (en) *	1997-12-12	1998-12-22	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) *	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) *	1998-01-14	2000-04-04	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) *	1998-01-27	1999-08-24	Cell Pathways, Inc.	Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) *	1998-04-15	1999-11-23	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en)	1998-08-14	2001-01-30	Cell Pathways, Inc.	[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) *	1998-09-11	2000-09-26	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en)	1998-09-11	2001-07-31	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6743443B1 (en) *	1998-10-05	2004-06-01	Eisai Co., Ltd.	Tablets immediately disintegrating in the oral cavity
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) *	1999-08-03	2000-10-10	Cell Pathways, Inc.	Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
GB9924020D0 (en)	1999-10-11	1999-12-15	Pfizer Ltd	Pharmaceutically active compounds
US6555547B1 (en)	2000-02-28	2003-04-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en)	2000-03-03	2003-05-27	Cell Pathways, Inc	Method for screening compounds for the treatment of neoplasia
DE50209015D1 (de) *	2001-05-09	2007-02-01	Bayer Healthcare Ag	NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
US6479493B1 (en)	2001-08-23	2002-11-12	Cell Pathways, Inc.	Methods for treatment of type I diabetes
EP1312363A1 (en) *	2001-09-28	2003-05-21	Pfizer Products Inc.	Methods of treatment and kits comprising a growth hormone secretagogue
US7342884B2 (en) *	2002-03-13	2008-03-11	Harmonic, Inc.	Method and apparatus for one directional communications in bidirectional communications channel
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) *	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US20050148034A1 (en) *	2002-04-12	2005-07-07	Hariri Robert J.	Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US20050118715A1 (en) *	2002-04-12	2005-06-02	Hariri Robert J.	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DE10232113A1 (de) *	2002-07-16	2004-01-29	Bayer Ag	Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de)	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit kontrollierter Bioverfügbarkeit
US20090186896A1 (en) *	2005-09-29	2009-07-23	Bayer Healthcare Ag	PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2167057A1 (en) *	2007-06-13	2010-03-31	Bayer HealthCare AG	Pde inhibitors for the treatment of hearing impairment
MX2010010334A (es) *	2008-03-24	2010-10-08	Celgene Corp	Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2011081915A2 (en) *	2009-12-15	2011-07-07	Cebix Inc.	Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es)	2011-03-01	2018-06-27	Synergy Pharmaceuticals Inc Star	Proceso de preparacion de agonistas c de guanilato ciclasa.
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
EP3004138B1 (en)	2013-06-05	2024-03-13	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6694385B2 (ja)	2013-08-09	2020-05-13	アーデリクス，インコーポレーテッド	リン酸塩輸送阻害のための化合物及び方法
WO2015200177A1 (en)	2014-06-23	2015-12-30	Celgene Corporation	Apremilast for the treatment of a liver disease or a liver function abnormality
US20200368223A1 (en)	2019-05-21	2020-11-26	Ardelyx, Inc.	Methods for inhibiting phosphate transport

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1425603A (fr) *	1964-01-18	1966-01-24	Kyowa Hakko Kogyo Kk	Procédé de préparation de dérivés de la purine
DE1545574A1 (de) *	1964-12-14	1969-07-31	Ajinomoto Kk	Verfahren zur Herstellung von Hypoxanthin und dessen Derivaten
GB1493685A (en) *	1970-12-15	1977-11-30	May & Baker Ltd	8-azapurinones
GB1338235A (en) *	1970-12-15	1973-11-21	May & Baker Ltd	Azapurinones
US3819631A (en) *	1970-12-15	1974-06-25	May & Baker Ltd	Azapurinones
DE3131365A1 (de) *	1981-08-07	1983-02-24	Henkel KGaA, 4000 Düsseldorf	Neue diglycidyl-substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung in arzneimittelzubereitungen mit cytostatischer wirksamkeit
US4565875A (en) *	1984-06-27	1986-01-21	Fmc Corporation	Imidazole plant growth regulators

1988
- 1988-01-26 CA CA000557327A patent/CA1303037C/en not_active Expired - Fee Related
- 1988-01-27 ES ES198888300696T patent/ES2033423T3/es not_active Expired - Lifetime
- 1988-01-27 DK DK040788A patent/DK40788A/da not_active Application Discontinuation
- 1988-01-27 DE DE8888300696T patent/DE3869205D1/de not_active Expired - Lifetime
- 1988-01-27 US US07/148,791 patent/US4885301A/en not_active Expired - Fee Related
- 1988-01-27 IE IE880213A patent/IE880213L/xx unknown
- 1988-01-27 EP EP88300696A patent/EP0293063B1/en not_active Expired
- 1988-01-28 PT PT86651A patent/PT86651B/pt not_active IP Right Cessation
- 1988-01-29 AU AU10956/88A patent/AU599452B2/en not_active Ceased
1992
- 1992-03-04 GR GR920400382T patent/GR3003956T3/el unknown

Also Published As

Publication number	Publication date
DE3869205D1 (de)	1992-04-23
ES2033423T3 (es)	1993-03-16
CA1303037C (en)	1992-06-09
PT86651B (pt)	1992-02-28
US4885301A (en)	1989-12-05
DK40788D0 (da)	1988-01-27
IE880213L (en)	1988-08-02
AU599452B2 (en)	1990-07-19
EP0293063B1 (en)	1992-03-18
AU1095688A (en)	1988-08-04
DK40788A (da)	1988-08-03
GR3003956T3 (pt)	1993-03-16
EP0293063A1 (en)	1988-11-30

Publication	Publication Date	Title
PT86651A (pt)	1988-02-01	Chemical compounds
NO172440C (no)	1993-07-21	Kjemisk forbindelse
DK90788D0 (da)	1988-02-22	Kemiske forbindelser
DK85993A (da)	1993-07-20	2-anilino-4-formyl-pyrimidinforbindelser
BA98296A (bs)	2001-09-14	Piperazinil-heterociklicna jedinjenja
DK666188A (da)	1988-11-29	Kemiske formuleringer
DK583684A (da)	1985-06-07	Kemiske forbindelser
DK594687D0 (da)	1987-11-12	Pyrrolidinylthioforbindelser
DK406586D0 (da)	1986-08-26	Kemiske forbindelser
DK356686A (da)	1987-01-28	Kemiske forbindelser
DK96986D0 (da)	1986-03-04	Kemiske forbindelser
DK593088A (da)	1989-04-27	Organiske forbindelser
DK301885D0 (da)	1985-07-02	Kemiske forbindelser
NO880809L (no)	1988-08-26	Antihyperkolesterolemiske tetrazolforbindelser.
PT84187A (pt)	1987-02-01	Novel compounds
DK483689D0 (da)	1989-10-02	Kemiske forbindelser
DK109886D0 (da)	1986-03-10	Kemiske forbindelser
PT86766A (pt)	1988-03-01	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
IT1221792B (it)	1990-07-12	Composti metossimetilici
DK346186D0 (da)	1986-07-21	Kemiske forbindelser
ATE93512T1 (de)	1993-09-15	Oximino-aether-verbindungen.
DK375287D0 (da)	1987-07-17	Fungicid indeholdende substituerede thienylaminer
DK519188D0 (da)	1988-09-16	Kemisk forbindelse
DE3878192D1 (de)	1993-03-18	N-phenyltetrahydrophthalimidverbindungen.
DK182587A (da)	1987-10-11	3-diphenyl-substituerede octahydroindolizinforbindelser

Legal Events

Date	Code	Title	Description
1992-02-28	FG3A	Patent granted, date of granting	Effective date: 19910808
1994-07-29	MM3A	Annulment or lapse	Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 19940228

Date

Code

Title

Description

1992-02-28

FG3A

Patent granted, date of granting

Effective date: 19910808

1994-07-29

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940228